MENU
+Compare
GRFS
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$9.23
Change
+$0.39 (+4.41%)
Capitalization
8.17B

GRFS Grifols SA Forecast, Technical & Fundamental Analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GRFS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GRFS with price predictions
Jan 13, 2026

GRFS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on January 13, 2026

GRFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where GRFS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for GRFS crossed bullishly above the 50-day moving average on December 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 192 cases where GRFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where GRFS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on January 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRFS as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GRFS turned negative on January 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

GRFS moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.043) is normal, around the industry mean (9.577). P/E Ratio (14.511) is within average values for comparable stocks, (24.549). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (2.006). Dividend Yield (0.019) settles around the average of (0.026) among similar stocks. P/S Ratio (0.718) is also within normal values, averaging (3.942).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

View a ticker or compare two or three
GRFS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

GRFS is expected to report earnings to rise 36.05% to 28 cents per share on February 26

Grifols SA GRFS Stock Earnings Reports
Q4'25
Est.
$0.29
Q3'25
Missed
by $0.03
Q2'25
Est.
$0.22
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
The last earnings report on November 04 showed earnings per share of 21 cents, missing the estimate of 24 cents. With 1.05M shares outstanding, the current market capitalization sits at 8.17B.
A.I.Advisor
published Dividends

GRFS paid dividends on August 20, 2025

Grifols SA GRFS Stock Dividends
А dividend of $0.18 per share was paid with a record date of August 20, 2025, and an ex-dividend date of August 12, 2025. Read more...
A.I. Advisor
published General Information

General Information

a manufacturer of plasma-derived biological medicines

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VIMAX370.840.32
+0.09%
Vanguard Mid Cap Index Admiral
FGIYX12.08-0.02
-0.17%
Nuveen Global Infrastructure I
MECVX15.83-0.05
-0.31%
NYLI Epoch Capital Growth Investor Class
NCIGX36.44-0.12
-0.33%
Nuveen International Value C
QILGX42.63-0.20
-0.47%
Federated Hermes MDT Large Cap Growth IS

GRFS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-3.28%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
GILD - GRFS
28%
Poorly correlated
-0.69%
PFE - GRFS
28%
Poorly correlated
-0.47%
BIIB - GRFS
28%
Poorly correlated
-3.95%
More